Fill in your details to access the 2018 sponsorship brochure, containing details of all our available commercial opportunities.
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. For more information, please visit www.roche.com.
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) represents research-based pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Research-based pharmaceutical companies make a unique contribution to global health as innovators of life-saving and life-changing medicines and vaccines, which improved millions of lives around the world. Both IFPMA and its companies are involved in hundreds of partnerships, including the new Access Accelerated initiative, a partnership of over 20 biopharmaceutical companies developing innovative and sustainable solutions to improve access to non-communicable disease (NCDs) treatment and care in low- and middle income countries. Access Accelerated also partners with the World Bank and the Union of International Cancer Control to help address the full spectrum of access barriers to NCD medicines. These partnerships involve the discovery of treatments that threaten health security or unduly put a burden on low income countries, as well as support Universal Health Coverage (UHC) by expanding access to medicines and vaccines and strengthening health systems and in doing so, contribute to the Sustainable Development Goals (SDG 3 and SDG 17).
IFPMA hosts the Secretariat of the AMR Industry Alliance, a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap and measures progress made in the fight against antimicrobial resistance. Other initiatives supported by IFPMA include: The African Global Health Leaders Fellowship and Fight the Fakes.
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance. Elsevier enhances the quality of research output by organizing the review, editing and dissemination of 17% of the world’s scientific articles. Our goal is to expand the boundaries of knowledge for the benefit of humanity.
BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become the largest genomic organization in the world. With a focus on research and applications in the health care, agriculture, conservation, and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated over 1,949 publications, many in top-tier journals such as Nature and Science.
Campus Biotech is a new centre of excellence in biotechnology and life science research focusing on Neurosciences, Neurotechnology, Digital and Global Health. Founded in 2013 by a Consortium composed by the Swiss Federal Institute of Technology in Lausanne (EPFL), the University of Geneva (UNIGE), the Bertarelli Family and Hansjörg Wyss, the Campus functions like a giant incubator and focuses on pure science and its translation into practical outcomes that have an impact on society and the world. In fact, Campus Biotech was created and purpose build to cross boundaries between disciplines and sectors, providing a unique ecosystem and a dynamic place dedicated to the translation of ideas into real solutions.
Partners and scientists based at Campus Biotech become part of a diverse, dynamic culture of knowledge exchange.
The Campus is expected to generate a vast range of opportunities, bringing impetus and investment to this vital economic and scientific sector.